Journal Article

HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions

Aldea, Marta, Glickman, Ariel, del Pino, Marta, Marimon, Lorena, Llupià, Anna, Ordi, Jaume, Henere, Carla, Manzotti, Carolina, Torné, Aureli, Saco, Adela, Rakislova, Natalia, Martí, Cristina

2022

Overview

Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment.

• Publisher: MDPI AG,MDPI
• Subject: Biopsy / Cellular biology / Cervix / Clinical outcomes / excisional treatment / HPV vaccine / Human papillomavirus / Immunization / Infections / Performance evaluation / post-treatment HSIL / Questions / Vaccination / Vaccines / Womens health